Clinical Trials Using Ziv-Aflibercept

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Ziv-Aflibercept. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • Pembrolizumab and Ziv-aflibercept in Treating Patients with Advanced Solid Tumors

    This phase I trial studies the side effects and best dose of ziv-aflibercept when given together with pembrolizumab in treating patients with solid tumors that have spread to other places in the body. Ziv-afibercept works by decreasing blood and nutrient supply to the tumor, which may result in shrinking the tumor. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving ziv-aflibercept together with pembrolizumab may be a better treatment for patients with advanced solid tumors.
    Location: 3 locations

  • Ziv-aflibercept and Octreotide Pamoate in Treating Patients with Metastatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

    This phase II trial studies how well ziv-aflibercept and octreotide pamoate works in treating patients with neuroendocrine tumors that cannot be removed by surgery. Ziv-aflibercept may stop the growth of neuroendocrine tumors by blocking blood flow to the tumor. Octreotide pamoate may block the use of a hormone called somatostatin by the tumor cells. Giving ziv-aflibercept together with octreotide pamoate may be an effective treatment for neuroendocrine tumors.
    Location: 3 locations

  • Sapanisertib and Ziv-Aflibercept in Treating Patients with Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

    This phase I trial studies the side effects and best dose of sapanisertib and ziv-aflibercept in treating patients with solid tumors that have come back and have spread to another place in the body or cannot be removed by surgery. Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ziv-aflibercept may stop the growth of solid tumors by blocking the growth of new blood vessels necessary for tumor growth. Giving sapanisertib with ziv-aflibercept may kill more tumor cells.
    Location: M D Anderson Cancer Center, Houston, Texas